JNJ-78911118 是一种强效、可穿透血脑屏障的选择性 GluN2A 拮抗剂(IC50 = 44 nM),对 GluN1/2B、2C 和 2D 受体的选择性超过 200 倍,作为负性变构调节剂(NAM)能够显著抑制谷氨酸在 GluN1/2A 受体上的效力并降低甘氨酸的效力,在体内产生显著的药效学效应,可用于抑郁症的相关研究。
产品编号: MS-G49418 纯度: 99.38% CAS No.: 3106013-91-3 分子式: C19H16ClF2N5O2 分子量: 419.81
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

JNJ-78911118 是一种强效、可穿透血脑屏障的选择性 GluN2A 拮抗剂(IC50 = 44 nM),对 GluN1/2B、2C 和 2D 受体的选择性超过 200 倍,作为负性变构调节剂(NAM)能够显著抑制谷氨酸在 GluN1/2A 受体上的效力并降低甘氨酸的效力,在体内产生显著的药效学效应,可用于抑郁症的相关研究。

生物实验数据

生物活性 JNJ-78911118 is a potent, brain-penetrant selective GluN2A antagonist (IC50 = 44 nM) with over 200-fold selectivity for GluN1/2B, 2C, and 2D receptors; as a negative allosteric modulator (NAM), it significantly inhibits glutamate efficacy and reduces glycine efficacy at GluN1/2A receptors, produces significant pharmacodynamic effects in vivo, and can be used for research related to depression.
IC50 & Target

GluN2A

44 nM (IC50)

体外研究
(In Vitro)

JNJ-78911118 (10 pM-10 μM,2 小时) 以浓度依赖的方式置换海马神经元膜上与放射性配体 JNJ-74950343 结合的 GluN1/2A 界面,不改变谷氨酸的效力,但降低其对同源 GluN1/2A 受体的活性。
JNJ-78911118 (10 μM,24-72 小时) 促进大鼠海马神经元培养物中神经突的生长和突触的形成,并在 72 小时后显著增强树突复杂性的多种指标。
JNJ-78911118 (1-10 μM) 在包含 77 个离子通道、受体和转运体的定制筛选面板以及一个包含 373 个激酶的面板中,对所有靶点均显示出低于 50 % 的抑制率。

体内研究
(In Vivo)

JNJ-78911118 (60 mg/kg,皮下注射,单次给药) 可减轻弗氏完全佐剂 (CFA) (MS-E83942) 诱导的炎症性疼痛小鼠模型中的机械性痛觉过敏,可抑制大鼠海马长时程增强作用,并增加大鼠前额叶皮层的微型兴奋性突触后电流 (mEPSC) 频率。
JNJ-78911118 (50 和 250 mg/kg,口服,每日两次,连续 4 天或同一天两次) 在大鼠中总体耐受性良好,但会产生剂量相关的血流动力学效应。

Animal Model: Male C57BL/6 N mice (8-12 weeks)
Dosage: 60 mg/kg
Administration: s.c., single dose 2 days post-CFA
Result: Partly reversed CFA induced allodynia at 60 mg/kg, while Gabapentin (MS-M83397) (150 mg/kg, p.o.) completely reversed it.
Reduced tactile allodynia at 30 min and 1 h post-administration compared to controls.
Had no effect on paw withdrawal thresholds (PWTs) 24 h post-dosing.
Animal Model: Wild-type C57BL/6J and homozygous Grin2a KO mice
Dosage: 60 mg/kg
Administration: s.c., single dose 2 days post-CFA
Result: Mitigated CFA-induced allodynia in wild type mice at 30 min and 1-h post-administration.
Did not significantly reduce CFA-induced mechanical allodynia in Grin2a KO mice.
Animal Model: Male Sprague-Dawley rats (8-10 weeks)
Dosage: 60 mg/kg
Administration: s.c., single dose 30 min pre-TBS
Result: Did not alter baseline synaptic transmission but completely blocked the induction of LTP by theta burst stimulation (TBS).
The population spike amplitude remained at pre-stimulation levels throughout the recording period (50-60 min post-TBS).
Animal Model: Male Sprague-Dawley rats (6-10 weeks)
Dosage: 60 mg/kg
Administration: s.c., single dose (24 h before recording)
Result: Induced a significant decrease in the inter-event interval of mEPSCs in layer 5 pyramidal neurons in rat medial prefrontal cortex.
Showed no significant changes in mEPSC amplitude.
Animal Model: Male Wistar Han rats
Dosage: 50 and 250 mg/kg
Administration: p.o., twice daily for 4 days
Result: Achieved dose-dependent plasma exposures, with Cmax and AUC increasing less than dose proportionally (80 and 180 %, respectively, and Tmax occurring 1-3 h post-dose.
Minimal activity decreases or minimal hypoactivity were observed 2 h post-dose on days 1-3.
Piloerection was observed in high-dose animals on Day 1 at 3 h post-dose.
Low doses had no effect on body weight, while the high dose caused a transient 3% decrease in two animals and lower overall body weight gain in all animals.
No meaningful changes were detected in globulin, protein, albumin, chloride, calcium and potassium concentrations, cholesterol level or reticulocyte count.
Produced mild decreases in triglyceride levels.
Showed no Olney's lesions in animals.
Animal Model: Male Sprague-Dawley rats (8-10 weeks)
Dosage: 50 and 250 mg/kg
Administration: p.o., twice on the same day
Result: The low dose increased heart rate and mean arterial pressure.
The high dose caused a transient decrease in heart rate (associated with reduced body temperature) and an increase in blood pressure.
性状 固体
颜色 White to off-white

化学信息

分子量 419.81
分子式 C19H16ClF2N5O2
CAS No. 3106013-91-3

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (238.20 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.3820 mL11.9101 mL23.8203 mL59.5507 mL
5 mM0.4764 mL2.3820 mL4.7641 mL11.9101 mL
10 mM0.2382 mL1.1910 mL2.3820 mL5.9551 mL
15 mM0.1588 mL0.7940 mL1.5880 mL3.9700 mL
20 mM0.1191 mL0.5955 mL1.1910 mL2.9775 mL
25 mM0.0953 mL0.4764 mL0.9528 mL2.3820 mL
30 mM0.0794 mL0.3970 mL0.7940 mL1.9850 mL
40 mM0.0596 mL0.2978 mL0.5955 mL1.4888 mL
50 mM0.0476 mL0.2382 mL0.4764 mL1.1910 mL
60 mM0.0397 mL0.1985 mL0.3970 mL0.9925 mL
80 mM0.0298 mL0.1489 mL0.2978 mL0.7444 mL
100 mM0.0238 mL0.1191 mL0.2382 mL0.5955 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础